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A major goal in diabetes research is to ﬁnd ways to enhance the
mass and function of insulin secreting b-cells in the endocrine
pancreas to prevent and/or delay the onset or even reverse overt
diabetes. In this Perspectives in Diabetes article, we highlight the
contrast between the relatively large body of information that is
available in regard to signaling pathways, proteins, and mecha-
nisms that together provide a road map for efforts to regenerate
b-cells in rodents versus the scant information in human b-cells.
To reverse the state of ignorance regarding human b-cell signal-
ing, we suggest a series of questions for consideration by the
scientiﬁc community to construct a human b-cell proliferation
road map. The hope is that the knowledge from the new studies
will allow the community to move faster towards developing
therapeutic approaches to enhance human b-cell mass in the
long-term goal of preventing and/or curing type 1 and type 2 di-
abetes. Diabetes 61:2205–2213, 2012
THE CHALLENGE OF INDUCING HUMAN b-CELL
REPLICATION
A principal goal of the National Institutes of Health/
National Institute of Diabetes and Digestive and Kidney
Diseases, Juvenile Diabetes Research Foundation, American
Diabetes Association, and their European and Asian
equivalents is to develop viable therapeutic approaches
to induce adult human b-cell replication/expansion for
regeneration therapies in patients with type 1 diabetes
and/or type 2 diabetes mellitus (T2DM). Unfortunately, all
observers of adult human b-cell replication ﬁnd that it is
very limited (;0.2% of b-cells/24 h) and poorly responsive
or unresponsive to the many mitogens, growth factors, and
nutrients that have been shown to induce expansion in
rodent models. For example, glucagon-like peptide-1
(GLP-1) and its analog, exendin-4, hepatocyte growth
factor (HGF), lactogens, insulin, IGF-I, and many other
molecules have been shown to increase rat and mouse
b-cell proliferation and mass expansion, but have shown
limited effects in human b-cells.
SPECIES- AND AGE-RELATED FAILURE OF b-CELL
REPLICATIVE CAPACITY
Some of this refractoriness to proliferation in both rodents
and humans is age-related. For example, whereas b-cell
replication is easy to induce using exendin-4 or partial
pancreatectomy in young mice, it is markedly attenuated
in older mice (1). Similarly, whereas b-cell replication has
been difﬁcult to induce in adult human b-cells, reports of
human embryonic and neonatal b-cell proliferation do
indicate that proliferation can occur in juvenile human
b-cells (2,3). But even in this study, the proliferation is very
limited (;2–4% in embryonic human b-cells by Ki-67
staining) as compared with other fetal and adult tissues
(e.g., spleen, bone marrow, gastrointestinal crypts, basal
keratinocytes) where proliferation is often 10-fold higher.
In contrast, there are also clear species differences,
because rodent b-cell models can display relatively large
proliferative responses (e.g., 10–15%), whereas this type of
proliferation is never seen in human b-cells under physi-
ological conditions, even in embryonic life. Perhaps more
germane to human diabetes, whatever the underlying
reasons, these issues are a major hurdle to driving thera-
peutic human b-cell expansion, because the major source
of human b-cells is adult cadaveric donors, and the major
therapeutic target for expansion of endogenous human
b-cells, at least initially, will be adults with type 1 diabetes
mellitus. Thus, there is an urgent need to understand why
adult b-cells are refractory to replication, and, at the end of
this Perspectives in Diabetes article, we suggest a series
of questions to be addressed by the scientiﬁc community
to reverse this state of ignorance.
THE RODENT b-CELL RECEPTOR–NUTRIENT–
SIGNALING–CELL-CYCLE PATHWAY ROAD MAP
In rodent b-cells, we have an impressive and expanding
intracellular signaling road map, or “wiring diagram,” that
reveals how proliferation normally occurs, how it inter-
sects with downstream cell-cycle machinery, and how it
can be manipulated for therapeutic purposes. Space pre-
vents a detailed discussion of every pathway, but several




kinase/Akt signaling. Insulin and IGF-I constitute two
primary members of the growth factor family for which
receptors are expressed ubiquitously and mediate the
growth and metabolic effects of the hormones in virtually
all mammalian tissues. Insulin and IGF-I classically bind to
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PERSPECTIVES IN DIABETEStheir own receptors, but can also cross-react and activate
common downstream proteins. Receptor activation trans-
mits signals by phosphorylating insulin receptor substrates
(IRS), including the four IRS proteins—Shc, Gab-1, focal
adhesion kinase, and Cbl—and others, leading to activa-
tion of phosphatidylinositol-3 kinase (PI3K)/Akt (see be-
low). Several recent reviews provide an excellent resource
for interested readers (4,5). Mouse b-cells express both the
insulin and IGF-I receptors, and most components of their
signaling pathways. Recent studies on insulin receptor (IR)
signaling in b-cells have provided cumulative evidence for
an autocrine role of insulin on its own receptor. Two early
mouse models that provided direct genetic evidence for
a role for insulin/IGF-I signaling in the regulation of b-cell
biology include the b-cell–speciﬁc knockout of the IR
(bIRKO) (6) and the global knockout of IRS-2 (7). Both
bIRKO and IRS2KO mice failed to maintain their b-cell
mass and manifested a phenotype most resembling human
T2DM. Following these two studies, multiple laboratories
have reported the creation and characterization of trans-
genics/KOs complemented by in vitro and ex vivo ap-
proaches to indicate the signiﬁcance of proteins in the
insulin/IGF-I cascade for the regulation of b-cells (5).
Contrary to traditional thought, we and others have used
genetic approaches to directly demonstrate that the
insulin/IGF-1 signaling pathway is not critical for early
development of b-cells (5,8). However, whereas both
bIRKO and b-cell–speciﬁc IGF-1 receptor KO mice exhibit
impaired glucose tolerance and secretory defects, only
bIRKO mice show an age-dependent decrease in b-cell
mass and an increased susceptibility to develop overt
diabetes, suggesting a dominant role for insulin signaling
in the regulation of adult b-cell mass (9). It has been ob-
served for several decades that mouse models of diabetes
and obesity exhibit a remarkable ability to compensate for
the increase in insulin demand in response to insulin
resistance. One such model, the liver-speciﬁcI RK O
mouse, develops severe insulin resistance and glucose in-
tolerance, but the mice do not become overtly diabetic
due, in part, to an ;30-fold increase in b-cell mass as
a compensatory mechanism to counter the ambient insulin
resistance (9,10).
The IRSs and Akt, important downstream signaling
molecules in the IR/IGF-I receptor signaling pathway, have
been reported to play a dominant role in b-cell growth.
Indeed, global KO of IRS-1 in mice leads to postnatal
growth retardation and hyperplastic and dysfunctional
islets, but the mice do not develop overt diabetes due to
b-cell compensation (11–13). In contrast, IRS-2 global KOs
develop mild growth retardation and, depending on their
genetic background, develop either mild glucose in-
tolerance or b-cell hypoplasia and overt diabetes (7,14).
b-cell–speciﬁc deletion of IRS-2 also leads to mild diabetes
(15). Importantly, IRS-2 mediates the effects of the incretin
hormone, GLP-1, to promote survival and/or proliferation
of rodent b-cells (16). Thus, IRS-2 appears to be a positive
regulator of b-cell compensation, whereas IRS-1 pre-
dominantly regulates insulin secretion.
FIG. 1. A working model depicting some of the multiple signaling pathways that have been reported to modulate cell-cycle activation and/or
proliferation in rodent b-cells. Note that although this model is reasonably robust, it is nonetheless preliminary and will require amendment and
addition over time. The growth factors (insulin, IGF-I, HGF) and the incretin hormone GLP-1 are linked to the IRS/PI3K pathway, which in turn
signals via PDK-1 to modulate Akt and FoxO1. Nutrients have also been reported to modulate PI3K, block AMP-activated protein kinase, and
modulate mTORC1. PI3K activation following HGF binding to its tyrosine kinase receptor, c-Met, results in the production of phosphatidylinositol
trisphosphate that directly binds to the pleckstrin homology domain of PDK-1. PDK-1 then attaches to the hydrophobic motif of PKCz, phos-
phorylates Thr410, and exposes the kinase domain to autophosphorylation of Thr560, a phosphorylation required for full catalytic activity. PKCz
activation leads to inactivation of GSK3b and increased phosphorylation and activation of mTORC1. Activation of mTORC1 is required for PKCz-
mediated induction of rodent b-cell proliferation. Lactogen signaling is activated by the prolactin receptor and acts via Jak2/Stat5 and/or Jak2/
Bcl6/menin and/or tryptophan hydroxylases, which generate serotonin. Serotonin is assumed to act via the HTR2b receptor to modulate
intracellular calcium and PKC or PI3K members. The FoxO proteins, downstream targets of Akt, are reported to regulate the cell cycle, although it is
unclear how this directly impacts b-cell cycle control. Transcriptional repression of cyclin D is required for FoxO-mediated inhibition of cell-cycle
progression and transformation, and FoxO proteins have been reported to upregulate the transcription of p27Kip1. The phosphorylation of FoxO1
by Akt is reported to prevent the transcription factor Foxa2 from driving the expression of Pdx1, which mediates the proliferation/differentiation
of b-cells in response to FoxO1 (90). Akt can also downregulate p21Cip1 activity indirectly through MDM2/p53. Insulin and IGF-I can also promote
proliferation independently of the PI3K pathway by acting through proteins that act by extracellular signal–related kinase-dependent and
-independent (Raf1) pathways. (A high-quality color representation of this ﬁgure is available in the online issue.)
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isoforms. Thus, global KOs for Akt2 develop overt diabetes
largely due to insulin resistance in peripheral tissues
and b-cell failure, despite islet hyperplasia and hyper-
insulinemia (17,18). Transgenic mice expressing a kinase-
dead mutant of Akt1 under control of the rat insulin I
promoter showed increased susceptibility to diabetes
following fat feeding (19). Islet hyperplasia, b-cell hy-
pertrophy, and hyperinsulinemia are observed in b-cell–
speciﬁc transgenic mice expressing constitutively active
Akt1 (20,21). Akt regulates proliferation by modulation of
multiple downstream targets including glycogen synthase
kinase-3 (GSK3) (see below), FoxO1, and tuberous sclerosis
proteins (TSC)/mammalian target of rapamycin (mTOR)
among others. Recent experiments have also linked the
cyclin/cyclin-dependent kinase (CDK) 4 complex to Akt
in b-cell proliferation, showing that Akt1 upregulates
cyclins D1 and D2, p21Cip1 levels (but not p27Kip1),
and CDK4 activity (22). Collectively, these in vivo data
suggest a dual role for the Akts in the regulation of
b-cell mass. In addition to regulating proliferation, class
Ia PI3K also modulates b-cell function by multiple
mechanisms (23).
GSK3 and liver kinase B1 signaling. GSK3 is a ubiqui-
tously expressed serine/threonine protein kinase originally
identiﬁed as a regulator of glycogen metabolism. It is now
well-established that GSK3 acts as a downstream regula-
tory switch for numerous signaling pathways and is in-
volved in cell-cycle regulation and cell proliferation. There
are two mammalian GSK3 isoforms encoded by distinct
genes: GSK3a and GSK3b. Activated Akt phosphorylates
and inactivates GSK3. GSK3 phosphorylation was ob-
served in mice overexpressing a constitutively active form
of Akt1 in b-cells (22), which correlated with an increase
in cyclin D1 levels in islets, suggesting that GSK3 is an
important negative regulator of b-cell cycle progression in
mice. Indeed, a decrease in GSK3b expression can correct
diabetes in mouse models of insulin resistance (24,25).
More recently, the GSK3b/b-catenin/T-cell factor pathway
has been shown to act in concert with cAMP-responsive
element–binding protein (CREB) to downregulate cyclin
D2 expression by phosphatase and tensin homolog (PTEN),
suggesting a convergence of the PI3K/PTEN and Wnt path-
ways. Furthermore, phosphorylation and activation of TSC2
by GSK3b inhibits mTOR signaling (26). However, whether
this occurs in b-cells is unknown.
Another kinase that physically associates in vivo with
GSK3b is the tumor suppressor liver kinase B1 (LKB1).
Loss of LKB1 in adult b-cells increases b-cell proliferation,
size, and mass and enhances glucose tolerance in mice
(27,28), suggesting that this kinase is a regulator of b-cell
growth in vivo in rodents. LKB1 is also known to asso-
ciate with protein kinase Cz (PKCz), as described below.
Whether there is any interaction among these three dif-
ferent kinases in the b-cell is currently unclear.
TSC, mTOR, S6 kinase, and 4E-BP1 signaling. mTORis
essential for cell growth and proliferation and is part of two
mTOR complexes (mTORC), mTORC1 and 2 [recently
reviewed (29)]. mTORC1 activity is negatively regulated by
TSC1, TSC2, and the small G protein Rheb. TSC2 phos-
phorylation and inactivation by Akt and extracellular
signal–related kinase, among other kinases, releases the
inhibition of Rheb, leading to activation of mTOR (29). In
contrast,phosphorylationandactivationofTSC2byseveral
kinases inhibits mTOR signaling (29). mTORC1 constitutes
the rapamycin-sensitive arm of mTOR signaling and
contains at least three proteins: raptor, mLst/GbL, and
PRAS40 (29). This pathway integrates signals from growth
factors and nutrients and controls growth (cell size), pro-
liferation (cell number), and metabolism by directly modu-
lating 4E-BP and S6 kinases (S6K) and by indirectly
attenuating Akt signaling via an mTORC1/S6K-mediated
negative-feedback loop on IRS signaling. S6K phosphor-
ylatesdownstreamsubstrates,suchasribosomalS6protein
and eukaryotic translation initiation factor 4B, to promote
mRNA translation and synthesis of ribosomes. Phosphory-
lation of 4E-BPs triggers their release from eukaryotic
translation initiation factor 4E and initiates cap-dependent
translation. Thus, mTORC1 substrates regulate cell growth,
proliferation, and mRNA translation initiation and pro-
gression, thereby controlling the rate of protein synthesis.
As relates to b-cells, evidence from mouse genetic
models demonstrates that mice with conditional deletion
of TSC2 (leading to mTORC1 activation) in b-cells exhibit
increases in b-cell mass, proliferation, and cell size (30).
Separate studies demonstrated that conditional deletion
of TSC2 or TSC1 in b-cells causes a similar phenotype,
but these mice developed diabetes and b-cell failure after
40 weeks (31,32). Further conﬁrmation of the effect of
mTORC1 activation to increase b-cell mass comes from
mice overexpressing Rheb in b-cells (33). However, pro-
liferation in b-cells with mTORC1 activation has not been
demonstrated in all studies: thus, precisely how mTORC1
acting upon 4E-BPs and S6K modulates b-cell mass, pro-
liferation, and function is unclear. Evidence for a role of
S6K in b-cell proliferation was demonstrated in mice with
activation of Akt signaling in an S6K1-deﬁcient back-
ground (34). However, S6K1 gain of function by transgenic
overexpression failed to induce proliferation, in part due
to negative feedback on IRS-1 and -2 signaling (35). The
importance of 4E-BPs on regulation of b-cell proliferation
is hard to decipher at present because of alterations in
insulin sensitivity in global KO models.
Further evidence for a role of mTORC1 in b-cell
proliferation comes from studies with its inhibitor, rapa-
mycin. These studies demonstrate that: 1) rapamycin
treatment blocks b-cell expansion, cell size, and pro-
liferation induced by activation of Akt in b-cells (36). The
inhibition of b-cell proliferation by rapamycin results from
decreases in cyclin D2 and D3 and in cyclin-dependent
kinase (cdk) 4 activity. 2) Rapamycin treatment results in
reduced proliferation in b-cells in pregnant mice and
causes antiproliferative effects on transplanted rat b-cells
in vivo (37,38). 3) Rapamycin also attenuates b-cell ex-
pansion in a model of insulin resistance and b-cell
regeneration (39,40) and reduces proliferation of rodent
islets in vitro (41). These studies support the concept that
mTORC1 pays an important role in the regulation of b-cell
mass and cell cycle and can mediate adaptation of b-cells
to insulin resistance.
The mTORC2 complex, containing rictor, mSin, and
protor, is insensitive to rapamycin. This complex phos-
phorylates Akt on Ser473, suggesting that this pathway
indirectly could be linked to proliferation. However, the
only evidence for a role for mTORC2 in b-cells comes from
mice with conditional deletion of rictor in b-cells (42).
These mice exhibit mild hyperglycemia resulting, in part,
from decreased b-cell proliferation, mass, and insulin
secretion.
Other pathways: PKCz signaling. PKCz is a member
of the atypical PKC subfamily activated by PI3K/39-PI-
dependent protein kinase-1 (PDK-1). Multiple studies
R.N. KULKARNI AND ASSOCIATES
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mitogenic signal transduction in a variety of cell types,
including ﬁbroblasts, brown adipocytes, endothelial cells,
and oocytes (43). More recently, the importance of PKCz
for b-cell replication has also been elucidated. We and
others have shown that growth factors such as GLP-1,
parathyroid hormone-related protein, HGF, and nutrients
such as glucose increase PKCz phosphorylation and ac-
tivity in insulinoma cells and rodent islets (44–46). In-
terestingly, activation of PKCz using a constitutively active
form of this kinase (CA-PKCz) markedly increases b-cell
proliferation in insulinoma and primary mouse b-cells in
vitro, suggesting that PKCz activation could be involved in
growth factor-induced rodent b-cell proliferation (45,46).
Indeed, small interfering RNA-based downregulation of PKCz
or the use of a dominant-negative form of PKCz completely
abolished growth factor-induced b-cell proliferation (45,46).
Conversely, transgenic mice with expression of CA-PKCz
in b-cells display increased b-cell proliferation, size, and
mass with a concomitant enhancement in insulin secretion
and improved glucose tolerance (47). Downstream, acti-
vation of mTOR and upregulation of cyclin Ds and A are
essential for PKCz-mediated mitogenic effects in rodent
b-cells (47). Collectively, these results indicate that PKCz
is a critical kinase for mitogenic signal transduction in
rodent b-cells in vitro and in vivo.
PKCz activation in rodent b-cells also leads to phosphor-
ylation and inactivation of GSK3b (47), suggesting that PKCz-
mediated b-cell mitogenic effects might also be favored by
GSK3b inactivation. GSK3b is one of the kinases known to
phosphorylate D-cyclins and to regulate their degradation
(48). Because PKCz activation results in increased GSK3b
phosphorylation/inactivation and increased expression
of D-cyclins, it is possible that PKCz increases the accumu-
lation of D-cyclins in b-cells through inactivation of GSK3b.
Lactogen and Janus kinase–signal transducer and
activation of transcription signaling. In rodent b-cells,
pregnancy-associated lactogens bind to the prolactin re-
ceptor, which then activates the Janus kinase JAK2, which
results in phosphorylation/activation of the transcription
factor signal transducer and activation of transcription 5
(STAT5) and its nuclear translocation. Phospho-STAT5
dimers bind to the promoter of the cyclin D2 gene and
upregulate transcription of cyclin D2 mRNA, with resultant
induction of b-cell proliferation. This pathway was dem-
onstrated to exist in rodent b-cells (49). More recently, two
reports have added depth and deﬁnition to this pathway.
First, Kim and colleagues (50) has demonstrated that lac-
togenic signaling during pregnancy upregulates the tran-
scription factor Bcl6, with resulting repression of the
epigenetic histone methylase complex, trithorax compo-
nent, menin. Through the trithorax complex, menin acts as
a transcriptional repressor of the CDK inhibitors p18INK4
and p27cip, and their repression is therefore permissive for
b-cell replication in pregnancy. Most recently, the German
group (Kim et al.) (51) has demonstrated that lactogenic
signaling during pregnancy also is associated with a dra-
matic, 1,0003, increase in serotonin production by b-cells,
ar e ﬂection of the induction of b-cell tryptophan hydrox-
ylases by lactogens. Unanswered questions still remain, such
as which signaling pathways does 5HT2b activate in the
b-cell? How exactly do these downstream signaling mole-
cules affect the cell-cycle symphony?
Additional growth factor signaling pathways. In this
brief Perspectives in Diabetes, only a few rodent b-cell
signaling pathways can be described. It should be clear,
however, that multiple other signaling pathways linking
growth factors to rodent b-cell replication exist. Examples
include: a glucose–glut2–ChREBP–cMyc pathway (52);
a glucose–AMP-activated protein kinase–LKB1–calcineurin–
nuclear factor of activated T-cell pathway (27,28,53); an
epidermal growth factor (EGF) ligand family (EGF, beta-
cellulin, heparin-binding EGF, amphiregulin, and trefoil
factor family 3)–EGF receptor–ras/raf–mitogen-activated
protein kinase (MAPK)–cdk–cyclin pathway (54,55); a cAMP–
cAMP-dependent protein kinase–CREB–cAMP response ele-
ment modulator–cyclin A pathway (56,57); parathyroid
hormone-related protein induction of proliferation (5); a
leptin–IRS-2 pathway (58); a transforming growth factor-b
activin family–SMAD pathway (59); sex hormone signaling
pathways (60); cannabinoid receptors (CB1) that cross-talk
with insulin receptors and IRS-2 (61) and calpains (62); and
recently, a platelet-derived growth factor (PDGF) receptor
linked to MAPK signaling pathway, driving the polycomb
repressive complex family member Ezh2, with repression of
p16INK4, thereby permitting activation of downstream cell-
cycle molecules such as the pRb family pocket proteins and
E2Fs (63).
CELL-CYCLE CONTROL OF PROLIFERATION IN THE
RODENT b-CELL
This is an important and rapidly moving area. It is complex
and well beyond the scope of a brief review, but detailed
reviews are available (64–66). Brieﬂy, downstream of ev-
ery developmental program and nutrient- or growth factor-
driven signaling pathway that is able to drive rodent b-cell
proliferation, intracellular signaling pathways converge on
the molecules that control the G1/S checkpoint. This
checkpoint is shown schematically in Fig. 2, and examples
of interactions with upstream signaling pathways are
shown in Fig. 3. Brieﬂy, there are a number of cell cycle–
activating molecules: the D-cyclins and their cognate cdks
FIG. 2. The rodent and human b-cell G1/S molecule road map. These are
the ultimate targets of upstream mitogenic signaling molecules. Those
that activate cell-cycle progression (cyclins and cyclin-dependent
kinases) are shown in green, and those that inhibit cell-cycle pro-
gression (the pocket proteins, INK4s, and the CIP/KIP families of
cell-cycle inhibitors) are shown in red. The two wiring diagrams in
rodents and human b-cells appear to be similar, with two exceptions
(cyclin D2 and cdk6), indicated in black: 1) human islets have little
cyclin D2, whereas this is abundant and critical in rodent b-cells; and 2)
human islets contain abundant cdk6, a cdk that is absent in rodent
b-cells. See text and references (64–66,71) for details. Modiﬁed from
Cozar-Castellano et al. (66). (A high-quality color representation of
this ﬁgure is available in the online issue.)
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Overexpression of all of these in various combinations is
able to drive rodent b-cell proliferation, either when de-
livered adenovirally (67) or transgenically, and in some
cases (but not all), disruption of their genes leads to b-cell
hypoplasia, hypoinsulinemia, and diabetes (64–66). Thus,
these cell-cycle activators are key targets of upstream
pathways, and they have been shown to be regulated by
these signaling pathways, growth factors (as described
above), and glucose and glucokinase activators (68).
These cell-cycle activators are balanced by a series of
cell-cycle inhibitors, which include the so-called “pocket
proteins” (pRb, p107, and p130), the INK4 family (p15, p16,
p18, and p19), the CIP/KIP family (p21, p27, and p57),
menin, and p53. The details of their actions and inter-
actions with the cyclins and cdks are too complex for
a brief discussion, but detailed reviews are available. The
key points in the current context are that they, too, are
essential regulators of b-cell cycle progression (e.g., p21
and p27 are regulated by mitogens and p16 and p18 by free
fatty acids), and genetic disruption of the genes encoding
some of these molecules leads to b-cell hyperplasia and
hyperfunction (69,70).
In this context, it is important to emphasize that these
G1/S molecules have short half-lives and frequently, if not
most often, are regulated at the level of protein stability.
This is important because changes seen at the mRNA level
frequently correlate poorly with those observed at the
protein level.
Thus, we know an enormous amount about cell-cycle
control in the rodent b-cell and how key signaling path-
ways regulate these molecules.
CELL-CYCLE CONTROL IN THE HUMAN b-CELL
As in the rodent b-cell, the G1/S molecules controlling
human b-cell proliferation have also been studied, and
much is now known. For example, we have a relatively
complete understanding of which of the ;30 G1/S mole-
cules are present in the human islet, and they can be
arranged in a working wiring diagram or road map, which
looks very similar to the rodent version in Fig. 2 (71). In
addition, we know that adenoviral overexpression of cer-
tain cell-cycle regulatory molecules (e.g., cMyc, the cdks,
or the cyclins D or E) in the human b-cell activates
proliferation robustly. For example, with adenoviral over-
expression of cell-cycle molecules, as many as 10–15% of
adult human b-cells are able to replicate as assessed using
Ki-67 immunohistochemistry or bromodeoxyuridine in-
corporation (71–74).
Although the human b-cell G1/S road map is similar to
that in the rodent b-cell, there are two principal differ-
ences, indicated by the black numbers in Fig. 2. First, cdk6
is absent in rodent b-cells but abundant in human b-cells
(71). This is relevant because genetic loss of cdk4 in mice
leads to b-cell hypoplasia and diabetes, presumably be-
cause there is no cdk6 to compensate for this loss. Second,
although all three D-cyclins are present in the mouse
b-cell, genetic loss of cyclin D2 (but not cyclins D1 or D3)
in mice leads to b-cell hypoplasia and diabetes, indicating
that this is the key D-cyclin in the rodent b-cell (75,76). In
contrast, human islets contain little or no cyclin D2 (71),
suggesting, paradoxically, either that cyclin D2 is irrele-
vant in the human b-cell or that it is absolutely
essential, with its paucity being precisely the reason that
human b-cells do not replicate.
Failure to signal from cell surface to cell-cycle ma-
chinery. Most importantly in the current context, be-
cause adult human b-cells do not replicate in response to
the long list of growth factors, nutrients, and maneuvers
that induce rodent b-cells to replicate, but clearly can rep-
licate when cyclins and cdks are overexpressed (71–73),
it is clear that failure or inadequacy of the cell-cycle
FIG. 3. Examples of reported upstream signaling pathways that activate cell-cycle progression in the rodent b-cell. This ﬁgure illustrates that there
are many different ways in which a growth factor or nutrient can activate cell-cycle progression. Please note that the ﬁgure is oversimpliﬁed for
clarity and is also incompletely deﬁned. The Akt/PKB, PKCz STAT5s, and b-catenin activate one or more cyclins and cdk proteins. MAPK has been
reported to modulate Ezh2 to act via p16. CREB/cAMP response element modulator, Nkx6.1 and Pdx1 have been reported to act via the “late” cdks
and cyclins, cdk1/2 and cyclins A/E. FoxM1 (91) has been reported to inhibit the Cip/Kip proteins, and menin, activate cMyc, and regulate Skp2
(92,93). PKCz activation in rodent b-cells leads to upregulation of cyclin Ds and A and diminished expression of p21. Modulation of one or more of
these cell-cycle proteins is critical for phosphorylation and inactivation of pRb so that it can release the E2F transcription factors that are required
for cell-cycle progression. Several additional b-cell mitogenic signaling pathways likely exist, including those activated by estrogen/progesterone
receptors, and JUN kinase (depicted as “?”). Green indicates proteins that promote proliferation, whereas red indicates proteins that inhibit
proliferation. (A high-quality color representation of this ﬁgure is available in the online issue.)
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replicate; the machinery is there and waiting to be acti-
vated. Thus, the likely missing link in adult human b-cell
replication is not failure to express key cell-cycle mole-
cules, but rather a failure to activate them in response to
what would appear to be appropriate upstream signals.
More speciﬁcally, the blockade(s) would appear to be
somewhere among the levels of the upstream growth fac-
tors, their receptors, signaling pathways that should, but
do not, alter these cell-cycle molecules.
THERE IS NO HUMAN b-CELL RECEPTOR–NUTRIENT–
SIGNALING–CELL-CYCLE PATHWAY ROAD MAP
If human b-cells possess the requisite G1/S molecules to
drive b-cell replication, and their upregulation can drive
human b-cell replication, it is then axiomatic that signaling
events that should be reaching the cell-cycle machinery
are not. It therefore would be particularly useful to have
a human b-cell signaling road map that describes these
intracellular signaling pathways, with their upstream
ligands and receptors and downstream cell-cycle targets.
Unfortunately, in contrast to the rich and complex road
map for growth factor and nutrient induction of rodent
b-cell replication, no such road map exists for the human
b-cell: we remain very much in the dark regarding recep-
tors, nutrient transporters/sensors, their downstream sig-
naling pathways, and their putative connections to the
ultimate downstream cell-cycle regulatory molecules.
Simply said, the human b-cell signaling road map is almost
a blank slate, a tabula rasa, as shown in the light gray lines
and text in the upper portion of Fig. 4, which should be
contrasted to their counterparts in Fig. 1. The following
sections brieﬂy summarize the little that we do know.
IRS-PI3K-Akt signaling. Human islet cells express in-
sulin and IGF-I receptors and components of these sig-
naling pathways (5,77). In functional terms, several studies
support the concept of a direct insulin action in the b-cell
that promotes a positive-feedback effect in vivo in healthy
humans (78) that is blunted in patients with T2DM (79,80).
Ex vivo examination of human islets and pancreas sec-
tions from T2DM patients (77,81) supports a role for the
insulin-signaling network in the regulation of cell-cycle
proteins. Although an increase in b-cell volume has been
reported in humans with obesity (82), it is unclear whether
this occurs as a compensatory response to insulin re-
sistance, as occurs in animal models, or is genetically
predetermined. Additional studies that directly address
this possibility are warranted.
mTORC1 and regulation of human b-cell prolifera-
tion. The expression of some mTOR signaling compo-
nents has been demonstrated in human islets (83)
exempliﬁed by its induction by glucose, amino acids, and
insulin (84). Most of our understanding of mTOR signaling
in human islets is derived from studies using rapamycin
derivatives as immunosuppressants or as treatment of
patients with insulinomas and other neuroendocrine
tumors. Rapamycin treatment has been shown to inhibit
human b-cell proliferation in vitro (41). Moreover, TSC2
and PTEN expression is decreased in insulinomas and
pancreatic endocrine tumors, suggesting that activation
of mTORC1 and Akt signaling plays a role in the pro-
liferative changes observed in these tumors (85). However,
insulinomas are rare in patients with tuberous sclerosis. In
contrast, mTORC1 inhibition by everolimus (a rapamycin
analog) improves glycemic control in patients with insulinoma
and prolongs progression-free survival in patients with
pancreatic neuroendocrine tumors (86,87). The extent to
which reduced b-cell mass or inhibition of insulin secre-
tion contributes to the responses to mTORC1 inhibition is
unclear, but, based on the current evidence, it is likely that
inhibition of b-cell proliferation plays a major role.
PKCz and GSK3 signaling in the human b-cell. Phar-
macological inhibition of GSK3b has been shown to
enhance (approximately fourfold) glucose-mediated human
FIG. 4. The rudimentary human b-cell mitogenic signaling road map. Contrast this ﬁgure to Fig. 1. The gray lines are molecules and pathways that
are known to exist in rodents but are unstudied in human b-cells. The human b-cell signaling road map is underdeveloped: Although the human G1/S
molecules are reasonably well-characterized in the human b-cell (66), only a handful of growth factor receptors (e.g., IR, IGF-1R, and c-Met) and
signaling molecules (IRS-1, IRS-2, PI3K, Akt, PKCz, and GSK3b) are known to be present in human b-cell, and the majority of the proteins involved
in signaling have not been studied.
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rates) (41), and adenoviral transduction of human islets
with CA-PKCz in vitro enhances (approximately fourfold)
human b-cell proliferation (45). However, whether PKCz-
induced human b-cell proliferation is mediated or poten-
tiated by GSK3b inactivation is unknown.
In summary, it is important to emphasize that at present,
although many examples exist in rodent b-cells, we do not
have a single example of a complete pathway in the human
b-cell that links a growth factor or nutrient, via a cell-
surface receptor through a complete signaling pathway, to
the downstream cell-cycle machinery that translates to
proliferation. In this regard, the recent report of a PDGF–
PDGF receptor–MAPK–Ezh2–p16 pathway (63) is exciting
and comes the closest to ﬁlling this void.
WHY WE NEED A HUMAN b-CELL MITOGENIC SIGNALING
PATHWAY ROAD MAP
Comparing Figs. 1 and 4 makes it clear that informed
efforts to drive therapeutic human b-cell proliferation are
severely hampered by the essentially complete lack of
a human b-cell road map. Further, the fact that direct cell-
cycle activation by cyclin/cdk overexpression can mark-
edly activate human b-cell proliferation places at least one
key obstacle to human b-cell proliferation within these
upstream signaling pathways, about which we know so
little. As noted below, it would be informative to in-
vestigate the upstream signaling pathways and identify
proteins that link the cell-surface receptors with key
molecules in the cell-cycle machinery in human b-cells.
Examples of key questions about which we have no
answers are: 1) do the gray molecules and lines in Fig. 4
even exist in adult human b-cells?; 2) are there key sig-
naling pathways in human islets that we have completely
overlooked? [e.g., erythropoietin, insulin, serotonin, and
osteocalcin have all been proposed as physiologic drivers
of rodent b-cell replication (51,88,89), but have not been
comprehensively tested in human b-cells]; 3) do adult
human b-cells require engagement of receptors or nu-
trients distinct from those on rodent b-cells; 4) what are
the intracellular signaling networks and cell-cycle targets
regulated by the kinases in Fig. 4 that are present in human
b-cells?; 5) are these kinases activated by growth factors
and nutrients, and, if not, what is preventing them from
being activated?; 6) can coordinate activation of combi-
nations of pathways synergize to enhance proliferation
(e.g., if overexpression of PKCz and inhibition of GSK3b
can increase human b-cell replication from 0.2 to 1.0%,
would coordinate activation of multiple pathways further
increase replication?)?; 7) are the cell-cycle inhibitors that
are so abundant in human b-cells restraining proliferation,
and how are they regulated?; 8) are key cell-cycle regula-
tory elements epigenetically regulated (in this study, for
example, the epigenetic methylases and demethylases
menin, Ezh2, and Bmi1 have all been shown to participate
in restraining rodent b-cell replication)?; 9) in this era of
high-throughput screening, which are the optimal small-
molecule targets in the human b-cell to drive proliferation?;
and 10) why and how do b-cells in young humans pro-
liferate at a higher rate compared with those from older
individuals?
The answers to these critical questions are simply that
we know very little: we have no road map from which to
hypothesize, model, and integrate data from multiple sys-
tems. We believe that obtaining the information required
to create such a road map is essential. Without this in-
formation, we are driving at night without headlights,
without a road map, and without global positioning system
navigation. It is time to develop such a high-content sig-
naling road map that connects the cell surface to cell-cycle
machinery in the human b-cell.
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